Undated
After leaving Genentech, Tessier-Lavigne joined the boards of Pfizer and Regeneron.
“I also joined two larger companies, the boards of Pfizer and Regeneron.”
Topic
9 facts from 2 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
Undated
After leaving Genentech, Tessier-Lavigne joined the boards of Pfizer and Regeneron.
“I also joined two larger companies, the boards of Pfizer and Regeneron.”
Undated
Aris Baras says Regeneron's analysis found that only about 10 percent of the roughly 20,000 human genes had ever been pursued as drug targets.
“There's 20 ,000 genes, and we'd only been able to really go after about 10%.”
Undated
Aris Baras says Regeneron has turned about 50 of the over 100 protective genetic discoveries into new medicines in its pipeline.
“We've taken about half of them or so, maybe 50, and turned them into new medicines over a decade now into Regeneron's pipeline.”
Undated
Aris Baras says Regeneron aspires to sequence 50 to 100 million people and must rethink how it collects data to do so.
“We're actually aspiring to get to 50 or 100 million. And now we have to rethink how we do this.”
Undated
Regeneron ran a 50,000-person proteomics pilot with UK Biobank and is extending protein measurement to all 500,000 participants.
“we do a 50 ,000 person proteomics study. Now we're completing that a couple of years later and doing everyone, all 500 ,000 in UK Biobank”
Undated
Collaborating with consumer genetics companies during COVID, Regeneron found genetic factors tied to severe COVID and hospitalization, and also protective factors, and published them.
“We found important genetic factors that could really put you at really high risk of getting severe COVID and hospitalizations.”
Undated
Aris Baras says it took about two and a half years from first patient dosed to approval for Regeneron's hearing-loss gene therapy.
“it was only two and a half years from the first patient dosed to getting that approval for me it's kind of a once in a career type of experience”
Undated
Regeneron, in partnership with Alnylam, has a late-stage siRNA drug designed to silence a liver-fat gene pronounced "side B."
“And we've got an sRNA in late stage development that's designed to silence and turn off side B.”
Undated
Aris Baras says Regeneron uses AI to improve variant calling, deciding which genetic changes are important.
“So we use AI, for example, to train and learn and help us be more accurate when we say, hey, this variant is important. It's called variant calling.”
Episodes